DE602004016444D1 - Azithromycin enthaltende pharmazeutische Zusammensetzungen mit verringerten Nebenwirkungen - Google Patents

Azithromycin enthaltende pharmazeutische Zusammensetzungen mit verringerten Nebenwirkungen

Info

Publication number
DE602004016444D1
DE602004016444D1 DE602004016444T DE602004016444T DE602004016444D1 DE 602004016444 D1 DE602004016444 D1 DE 602004016444D1 DE 602004016444 T DE602004016444 T DE 602004016444T DE 602004016444 T DE602004016444 T DE 602004016444T DE 602004016444 D1 DE602004016444 D1 DE 602004016444D1
Authority
DE
Germany
Prior art keywords
azithromycin
pharmaceutical compositions
side effects
reduced side
containing pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004016444T
Other languages
English (en)
Inventor
Leah Elizabeth Appel
Marshall David Crew
Dwayne Thomas Friesen
Timothy Arthur Hagen
Scott Max Herbig
Julian Belknap Lo
David Keith Lyon
Scott Baldwin Mccray
Avinash Govind Thombre
James Blair West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34468055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602004016444(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602004016444D1 publication Critical patent/DE602004016444D1/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
DE602004016444T 2003-12-04 2004-05-06 Azithromycin enthaltende pharmazeutische Zusammensetzungen mit verringerten Nebenwirkungen Active DE602004016444D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52708403P 2003-12-04 2003-12-04
US10/763,340 US6984403B2 (en) 2003-12-04 2004-01-23 Azithromycin dosage forms with reduced side effects

Publications (1)

Publication Number Publication Date
DE602004016444D1 true DE602004016444D1 (de) 2008-10-23

Family

ID=34468055

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004016444T Active DE602004016444D1 (de) 2003-12-04 2004-05-06 Azithromycin enthaltende pharmazeutische Zusammensetzungen mit verringerten Nebenwirkungen

Country Status (36)

Country Link
US (4) US6984403B2 (de)
EP (1) EP1537859B1 (de)
JP (2) JP4602711B2 (de)
KR (1) KR100906290B1 (de)
AR (1) AR045630A1 (de)
AT (1) ATE407663T1 (de)
BR (1) BRPI0403935B8 (de)
CA (1) CA2467611C (de)
CL (1) CL2004001501A1 (de)
CR (1) CR7500A (de)
CY (1) CY1108486T1 (de)
DE (1) DE602004016444D1 (de)
DK (1) DK1537859T3 (de)
DO (1) DOP2004000994A (de)
EA (1) EA010110B1 (de)
ES (1) ES2312929T3 (de)
GE (1) GEP20074056B (de)
HK (1) HK1080367B (de)
HR (1) HRP20040865A2 (de)
IL (1) IL164165A (de)
IS (1) IS2672B (de)
MA (1) MA27848A1 (de)
MX (1) MXPA04009424A (de)
NL (1) NL1026315C2 (de)
NO (1) NO20043903L (de)
NZ (1) NZ535464A (de)
OA (1) OA12858A (de)
PA (1) PA8611501A1 (de)
PE (1) PE20050573A1 (de)
PL (2) PL1537859T3 (de)
PT (1) PT1537859E (de)
RS (1) RS84704A (de)
SI (1) SI1537859T1 (de)
TW (1) TWI351969B (de)
UY (1) UY28509A1 (de)
WO (1) WO2005053650A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680356B2 (en) † 1994-05-06 1997-07-24 Pfizer Inc. Controlled-release dosage forms of azithromycin
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
MXPA05010817A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Formulaciones farmaceuticas que contienen metilnaltrexona.
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
DE602005003343T2 (de) * 2004-04-12 2008-09-11 Pfizer Products Inc., Groton Arzneiimittel mit verdecktem geschmack in aufbrechenden multipartikeln
EP1765292B1 (de) 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Gegen missbrauch gesicherte arzneimittelformulierungen
EP1782816B1 (de) * 2004-07-02 2011-10-19 Wakamoto Pharmaceutical Co., Ltd. Medizinische zusammensetzung auf wasserbasis mit azithromycin und herstellungsverfahren dafür
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060193908A1 (en) * 2004-11-09 2006-08-31 Burnside Beth A Extended release formulations of poorly soluble antibiotics
ES2714198T3 (es) * 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US20060252831A1 (en) * 2005-05-06 2006-11-09 Christopher Offen Method for the treatment of magnesium and potassium deficiencies
US20060252830A1 (en) * 2005-05-06 2006-11-09 Brandon Stephen F Method for the treatment of magnesium and potassium deficiencies
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
JP5252926B2 (ja) 2005-12-22 2013-07-31 大塚製薬株式会社 薬物含有ワックスマトリックス粒子の製造方法、該方法に使用されるエクストルーダー、及びシロスタゾールを含有する徐放性製剤
CN101340882B (zh) * 2005-12-22 2015-02-11 大塚制药株式会社 含有药物的蜡基质粒子的制造方法、用于该方法的挤出机、及含有西洛他唑的缓释制剂
AU2007256844A1 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US10357462B2 (en) * 2006-11-30 2019-07-23 Ben Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
JP5162134B2 (ja) * 2007-01-22 2013-03-13 愛媛県 機能性材料の製造方法、機能性材料、シート状構造体、及び衛生製品
CA2678367C (en) * 2007-03-02 2014-07-08 Farnam Companies, Inc. Sustained release compositions using wax-like materials
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
US20100305323A1 (en) 2007-03-29 2010-12-02 Smolenskaya Valeriya N Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
JP5461386B2 (ja) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 末梢オピオイド受容体アンタゴニストおよびその使用
DE102007026550A1 (de) * 2007-06-08 2008-12-11 Bayer Healthcare Ag Extrudate mit verbesserter Geschmacksmaskierung
DE102007034155A1 (de) * 2007-07-21 2009-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Vorrichtung mit mindestens einer Verpackungseinheit mit einem zur Radiofrequenz-Identifikation dienenden RFID-Chip und Verfahren dazu
JP5468015B2 (ja) 2008-01-08 2014-04-09 アクセリア ファーマシューティカルズ 抗菌ペプチド系に対する作動薬
EP2240489A1 (de) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. HERSTELLUNG UND VERWENDUNG VON (R), (R)-2,2ýBIS-METHYLNALTREXON
AU2009225434B2 (en) * 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
MX2011000862A (es) * 2008-07-21 2011-03-15 Otonomy Inc Composiciones antimicrobianas de liberacion controlada y metodos para el tratamiento de trastornos oticos.
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EP2314286A1 (de) * 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
PL2673237T3 (pl) 2011-02-11 2019-04-30 Zs Pharma Inc Zastosowanie krzemianu cyrkonu do leczenia hiperkaliemii
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
US9943637B2 (en) 2012-06-11 2018-04-17 ZS Pharma, Inc. Microporous zirconium silicate and its method of production
MX2015000381A (es) 2012-07-11 2015-11-23 Zs Pharma Inc Silicato de zirconio microporoso para el tratamiento de la hipercalemia en pacientes hipercalcemicos y composiciones con calcio mejoradas para el tratamiento de la hipercalemia.
US10695365B2 (en) 2012-10-22 2020-06-30 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia
CN104797263B (zh) 2012-10-22 2018-02-09 Zs制药公司 用于治疗高钾血症的微孔硅酸锆
CN106232126A (zh) * 2013-12-10 2016-12-14 Zs制药公司 用于治疗高钾血症、不共同施用锂的硅酸锆
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
PT3263106T (pt) 2015-02-25 2024-01-12 Eisai R&D Man Co Ltd Método para suprimir o amargor do derivado de quinolina
WO2016145067A1 (en) * 2015-03-10 2016-09-15 Lumos Pharma, Inc. Cyclocreatine microsuspension
US10286003B2 (en) 2015-06-10 2019-05-14 Piedmont Animal Health, Llc Injectable antibiotic formulations and use thereof
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
HRP20220856T1 (hr) 2016-03-15 2022-10-14 Acer Therapeutics Inc. Pripravci ugodna okusa uključujući natrijev fenilbutirat i njihove uporabe
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CA3051914A1 (en) * 2017-02-02 2018-08-09 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
EP3829640A4 (de) 2018-08-01 2022-05-25 McMaster University Verfahren zur hemmung von mikrobenwachstum
CN111643455A (zh) * 2020-06-22 2020-09-11 健民药业集团股份有限公司 一种阿奇霉素缓释干混悬剂及其制备方法
WO2022220669A1 (es) * 2021-04-16 2022-10-20 Garcia Perez Miguel Angel Combinación sólida oral para el tratamiento de infección por virus
CN114699386B (zh) * 2022-04-14 2023-05-23 深圳职业技术学院 阿奇霉素组合物及其制备方法

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6650A (en) * 1849-08-14 Edmund blunt
US25342A (en) * 1859-09-06 Justus k
US228357A (en) * 1880-06-01 Walter m
US165563A (en) * 1875-07-13 Improvement in snow-plows
US14951A (en) * 1856-05-27 Boot-tree
US26851A (en) * 1860-01-17 Improvement
US190365A (en) * 1877-05-01 Improvement in running-gear for vehicles
US3590A (en) * 1844-05-17 Rule or measure
US2955956A (en) * 1957-05-15 1960-10-11 Morton Salt Co Process and apparatus for coating granules
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
US4092089A (en) * 1974-04-06 1978-05-30 Bayer Aktiengesellschaft Apparatus for the preparation of melt-sprayed spherical phenacetin granules
US4053264A (en) * 1976-01-30 1977-10-11 United Technologies Corporation Apparatus for making metal powder
US4293570A (en) * 1979-04-02 1981-10-06 Chimicasa Gmbh Process for the preparation of sweetener containing product
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
KR920006865B1 (ko) * 1984-05-18 1992-08-21 워싱톤 유니버시티 테크놀러지 어소우시에이츠 인코오퍼레이티드 입자나 액적을 피복하는 방법과 장치
US4874611A (en) 1985-06-20 1989-10-17 The Dow Chemical Company Microencapsulated ant bait
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
US5100592A (en) * 1986-03-12 1992-03-31 Washington University Technology Associated, Inc. Method and apparatus for granulation and granulated product
US5387431A (en) * 1991-10-25 1995-02-07 Fuisz Technologies Ltd. Saccharide-based matrix
US5236734A (en) * 1987-04-20 1993-08-17 Fuisz Technologies Ltd. Method of preparing a proteinaceous food product containing a melt spun oleaginous matrix
US5456932A (en) 1987-04-20 1995-10-10 Fuisz Technologies Ltd. Method of converting a feedstock to a shearform product and product thereof
WO1989000576A1 (en) * 1987-07-09 1989-01-26 Pfizer Inc. Azithromycin dihydrate
WO1989002271A1 (en) 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5064650A (en) 1988-04-19 1991-11-12 Southwest Research Institute Controlled-release salt sensitive capsule for oral use and adhesive system
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
JPH03206039A (ja) * 1990-01-08 1991-09-09 Kyoto Yakuhin Kogyo Kk ニフェジピン持続性製剤
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
EP0452862B1 (de) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Kugelförmige Keimkerne, kugelförmige Granulate sowie Verfahren zu deren Herstellung
US5183690A (en) * 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
GB9014646D0 (en) 1990-07-02 1990-08-22 Courtaulds Coatings Holdings Coating compositions
US5194262A (en) * 1990-10-22 1993-03-16 Revlon Consumer Products Corporation Encapsulated antiperspirant salts and deodorant/antiperspirants
US5196199A (en) * 1990-12-14 1993-03-23 Fuisz Technologies Ltd. Hydrophilic form of perfluoro compounds and method of manufacture
US5292657A (en) * 1990-12-31 1994-03-08 Pioneer Hi-Bred International, Inc. Process for preparing rotary disc fatty acid microspheres of microorganisms
US5143662A (en) * 1991-02-12 1992-09-01 United States Surgical Corporation Process for preparing particles of bioabsorbable polymer
US5707546A (en) * 1991-06-17 1998-01-13 Rio Linda Chemical Co., Inc. Generation and storage of chlorine dioxide in a non-aqueous medium
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
GB9201857D0 (en) * 1992-01-29 1992-03-18 Smithkline Beecham Plc Novel compound
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
DE4214272A1 (de) * 1992-05-04 1993-11-11 Nukem Gmbh Verfahren und Vorrichtung zur Herstellung von Mikrokugeln
CA2095776C (en) * 1992-05-12 2007-07-10 Richard C. Fuisz Rapidly dispersable compositions containing polydextrose
EP0641195B1 (de) * 1992-05-22 1996-04-10 Gödecke Aktiengesellschaft Verfahren zur herstellung retardierter arzneimittelzubereitungen
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
TW271400B (de) * 1992-07-30 1996-03-01 Pfizer
US5348758A (en) * 1992-10-20 1994-09-20 Fuisz Technologies Ltd. Controlled melting point matrix formed with admixtures of a shearform matrix material and an oleaginous material
US5380473A (en) * 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
GB9224855D0 (en) * 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
US5569467A (en) 1993-05-15 1996-10-29 Societe De Conseils De Recherches Et D'applications (S.C.R.A.S.) Process for the preparation of microballs and microballs thus obtained
US5690959A (en) 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
US5597416A (en) * 1993-10-07 1997-01-28 Fuisz Technologies Ltd. Method of making crystalline sugar and products resulting therefrom
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5935600A (en) * 1993-09-10 1999-08-10 Fuisz Technologies Ltd. Process for forming chewable quickly dispersing comestible unit and product therefrom
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
JP4157969B2 (ja) * 1994-03-18 2008-10-01 スパーナス ファーマシューティカルズ インコーポレイテッド 乳化薬物送達システム
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
AU680356B2 (en) * 1994-05-06 1997-07-24 Pfizer Inc. Controlled-release dosage forms of azithromycin
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5582855A (en) 1994-07-01 1996-12-10 Fuisz Technologies Ltd. Flash flow formed solloid delivery systems
US5556652A (en) * 1994-08-05 1996-09-17 Fuisz Technologies Ltd. Comestibles containing stabilized highly odorous flavor component delivery systems
US5601761A (en) * 1994-09-26 1997-02-11 The Dow Chemical Company Encapsulated active materials and method for preparing same
US5493044A (en) * 1994-10-20 1996-02-20 Fmc Corporation Process for preparing alkylsilyl or arylsilyl ethers
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US6083430A (en) * 1994-10-28 2000-07-04 Fuisz Technologies Ltd. Method of preparing a dosage unit by direct tableting and product therefrom
US5683720A (en) 1994-10-28 1997-11-04 Fuisz Technologies Ltd. Liquiflash particles and method of making same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
FR2732621B1 (fr) * 1995-04-10 1997-06-06 Rhone Poulenc Chimie Perles d'un produit presentant le phenomene de surfusion et leur procede d'obtention
KR100404293B1 (ko) 1995-05-02 2004-02-18 다이쇼 세이야꾸 가부시끼가이샤 경구투여용조성물
US5883103A (en) * 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
WO1997002019A1 (en) * 1995-06-30 1997-01-23 Baylor University Polyester/carboxylic acid composite materials
EP0784933A3 (de) * 1995-10-16 1997-11-26 Leaf, Inc. Verlängerte Freigabe von Additiven in Nahrungsmittel
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5916582A (en) * 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
DE19629753A1 (de) * 1996-07-23 1998-01-29 Basf Ag Verfahren zur Herstellung von festen Arzneiformen
US6139872A (en) 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
HRP970485A2 (en) * 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
DE19652257A1 (de) * 1996-12-16 1998-06-18 Lohmann Therapie Syst Lts Einzeln dosierte, bei Kontakt mit Flüssigkeit schnell zerfallende, wirkstoff- und insbesondere aromastoffhaltige, folienförmige Darreichnungsform
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6656508B2 (en) * 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US5851555A (en) 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US5840334A (en) 1997-08-20 1998-11-24 Fuisz Technologies Ltd. Self-binding shearform compositions
US5980941A (en) 1997-08-20 1999-11-09 Fuisz Technologies Ltd. Self-binding shearform compositions
IT1294760B1 (it) * 1997-09-03 1999-04-12 Jagotec Ag Procedimento per la preparazione di compresse farmaceutiche in grado di cedere,secondo schemi predeterminabili, principi attivi poco
DE69828635T2 (de) * 1997-09-19 2005-06-16 Shire Laboratories, Inc. Feste lösungskügelchen
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
SI1037634T1 (sl) 1997-12-08 2006-02-28 Altana Pharma Ag Peroralna dajalna oblika, ki obsega inhibitor protonske crpalke (npr. pantoprazol)
US6270804B1 (en) * 1998-04-03 2001-08-07 Biovail Technologies Ltd. Sachet formulations
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
JPH11335300A (ja) * 1998-05-20 1999-12-07 Sumitomo Pharmaceut Co Ltd グリセリン脂肪酸エステルを使用した徐放性製剤
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6086920A (en) * 1998-08-12 2000-07-11 Fuisz Technologies Ltd. Disintegratable microspheres
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
CA2245398C (en) * 1998-08-21 2002-01-29 Apotex Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
US6165512A (en) 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
ES2229804T3 (es) * 1998-11-30 2005-04-16 Teva Pharmaceutical Industries Ltd. Etannolato de azitromicina, procedimiento para su fabricacion y composiciones farmaceuticas que lo contienen.
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP2003513019A (ja) * 1999-09-27 2003-04-08 ソーナス ファーマシューティカルス，インコーポレイテッド トコール可溶性治療剤の組成物
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
CA2469246A1 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Directly compressible formulations of azithromycin
MXPA04003027A (es) * 2001-12-21 2004-07-05 Pfizer Prod Inc Metodos para granulacion humeda de azitromicina.
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
AU2003201146B2 (en) * 2002-02-01 2008-04-17 Pfizer Products Inc. Dry granulated formulations of azithromycin
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
PL1648473T3 (pl) * 2003-07-24 2009-07-31 Pliva Hrvatska D O O Pojedyncza dawka szybko rozpuszczającej się azytromycyny

Also Published As

Publication number Publication date
CL2004001501A1 (es) 2005-05-13
NZ535464A (en) 2009-03-31
DOP2004000994A (es) 2005-06-30
CY1108486T1 (el) 2014-04-09
EP1537859A2 (de) 2005-06-08
TW200518784A (en) 2005-06-16
SI1537859T1 (sl) 2008-12-31
US20060039988A1 (en) 2006-02-23
US20050123627A1 (en) 2005-06-09
JP2005162733A (ja) 2005-06-23
MA27848A1 (fr) 2006-04-03
US6984403B2 (en) 2006-01-10
KR100906290B1 (ko) 2009-07-06
WO2005053650A1 (en) 2005-06-16
CA2467611C (en) 2010-03-30
OA12858A (en) 2006-09-15
EA010110B1 (ru) 2008-06-30
AR045630A1 (es) 2005-11-02
WO2005053650A8 (en) 2005-12-01
US20080015343A1 (en) 2008-01-17
UY28509A1 (es) 2005-07-29
RS84704A (sr) 2007-02-05
PL379984A1 (pl) 2006-11-27
DK1537859T3 (da) 2008-11-17
IS2672B (is) 2010-09-15
HK1080367B (zh) 2010-11-05
EA200401216A1 (ru) 2005-12-29
CA2467611A1 (en) 2005-06-04
MXPA04009424A (es) 2005-07-26
NL1026315C2 (nl) 2006-01-24
CR7500A (es) 2007-09-03
BRPI0403935B8 (pt) 2021-05-25
PA8611501A1 (es) 2005-08-04
GEP20074056B (en) 2007-03-12
PT1537859E (pt) 2008-11-18
KR20060033851A (ko) 2006-04-20
US20060029677A1 (en) 2006-02-09
EP1537859A3 (de) 2005-07-06
JP4602711B2 (ja) 2010-12-22
BRPI0403935B1 (pt) 2018-02-06
NL1026315A1 (nl) 2005-06-07
TWI351969B (en) 2011-11-11
BRPI0403935A (pt) 2005-08-09
JP2010132700A (ja) 2010-06-17
EP1537859B1 (de) 2008-09-10
PE20050573A1 (es) 2005-09-05
IS7464A (is) 2005-06-05
HRP20040865A2 (en) 2006-02-28
HK1080367A1 (en) 2006-04-28
ES2312929T3 (es) 2009-03-01
IL164165A0 (en) 2005-12-18
IL164165A (en) 2012-01-31
NO20043903L (no) 2004-11-09
ATE407663T1 (de) 2008-09-15
PL1537859T3 (pl) 2009-01-30

Similar Documents

Publication Publication Date Title
DE602004016444D1 (de) Azithromycin enthaltende pharmazeutische Zusammensetzungen mit verringerten Nebenwirkungen
DE602004025950D1 (de) Pharmazeutische formulierung mit lanthanum-verbindungen
DE602004017700D1 (de) Transmukosen verabreichung
DE602005012107D1 (de) Pharmazeutische formulierungen mit einem antibioti
ATE336264T1 (de) Dispergierbare pharmazeutische zusammensetzungen
DE60118008D1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
DE60316323D1 (de) Feste pharmazeutische formulierungen mit telmisartan
NO20031447D0 (no) Paclitaxel-basert antitumor-formulering
DE60332393D1 (de) Flüssige pharmazeutische zusammensetzung mit pyridonderivaten
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
DK1587478T3 (da) Farmaceutisk sammensætning
DE60305728D1 (de) PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VERLuNGERTER FREISETZUNG
ATE415949T1 (de) Pharmazeutische formulierung mit levothyroxin- natrium
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE518876T1 (de) Macrolid-konjugate mit entzündungshemmender wirkung
DE602004024220D1 (de) Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
DE602006017975D1 (de) Feste pharmazeutische zusammensetzung mit telithromycin
ATE504290T1 (de) Zusammensetzungen mit neramexan
ATE546141T1 (de) Pharmazeutisches injektionspräparat
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
DE10291905D2 (de) Pharmazeutische Zusammensetzung
NO20034952D0 (no) Farmasöytiske forbindelser
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
DE602005016105D1 (de) Pharmazeutische zusammensetzungen mit zd6474

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: FRIESEN, DWAYNE THOMAS, OREGON 97701, US

Inventor name: MCCRAY, SCOTT BALDWIN, BEND OREGON 97701, US

Inventor name: THOMBRE, AVINASH GOVIND, GROTON CONNECTICUT 06, US

Inventor name: WEST, JAMES BLAIR, BEND OREGON 97701, US

Inventor name: HERBIG, SCOTT MAX, GROTON CONNECTICUT 06340, US

Inventor name: APPEL, LEAH ELIZABETH, OREGON 97701, US

Inventor name: HAGEN, TIMOTHY ARTHUR, GROTON CONNECTICUT 0634, US

Inventor name: LO, JULIAN BELKNAP, GROTON CONNECTICUT 06340, US

Inventor name: LYON, DAVID KEITH, BEND OREGON 97701, US

Inventor name: CREW, MARSHALL DAVID, OREGON 97701, US

8364 No opposition during term of opposition